2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
August 16, 2021
Video
Christine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.
August 16, 2021
Video
Hung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer.
August 13, 2021
Article
Due to the potency of CAR T-cell therapies and the associated adverse events that can to arise in patients receiving this type of treatment, oncology nurses need to be educated on how to best identify and manage these AEs.
August 12, 2021
Video
Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.
August 12, 2021
Article
The widening treatment paradigm for various breast cancer subtypes is yielding improved survival with more tailored strategies.
August 11, 2021
Video
Martine Extermann, MD, PhD, discusses the utility of single-agent trastuzumab in HER2-positive breast cancer.
August 03, 2021
Video
Christine Sam, MD, shares strategies to manage interstitial lung disease experienced with fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.
August 02, 2021
Article
Moffitt Cancer Center is currently working to develop a host of novel therapeutic treatments within the breast cancer space, from immunotherapeutics to personalized cancer vaccines.
July 21, 2021
Video
David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.
July 20, 2021
Video
Ricardo Costa, MD, MSc, discusses ongoing research efforts in triple-negative breast cancer.
July 15, 2021
Article
David Sallman, MD, discusses the role of hypomethylating agents in the treatment of patients with higher-risk myelodysplastic syndrome, the promise of pevonedistat in this population, the hunt for biomarkers of response to treatment, and remaining areas of unmet need to address with future efforts.
July 14, 2021
Video
Jing-Yi Chern, MD, ScM, discusses outcomes with PARP inhibitors in patients with recurrent ovarian cancer.
July 13, 2021
Article
Sarabdeep “Sabi” Singh has been named executive vice president and chief operating officer of Moffitt Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida.
July 12, 2021
Video
David Sallman, MD, discusses unmet needs in the treatment of patients with higher-risk myelodysplastic syndromes.
July 07, 2021
Video
Bijal Shah, MD, MS, discusses efforts to combat resistance to BTK inhibitors in patients with mantle cell lymphoma.
June 29, 2021
Video
Kamran A. Ahmed, MD, discusses the need for multidisciplinary care in patients with HER2-positive breast cancer and leptomeningeal disease.
June 05, 2021
Article
A single infusion of brexucabtagene autoleucel, a CAR T-cell therapy, demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
June 03, 2021
Video
Bijal Shah, MD, MS, discusses shortcomings with BTK inhibitors in high-risk mantle cell lymphoma.
May 28, 2021
Article
Novel immunotherapy combinations are gaining ground in the frontline treatment of patients with lung cancer, but the toxicities associated with these regimens must be weighed against the benefit they provide.
May 25, 2021
Video
Jing-Yi Chern, MD, ScM, discusses future research directions in the treatment of patients with ovarian cancer.